ES2904787T3 - Composición para la estimulación ovárica controlada - Google Patents

Composición para la estimulación ovárica controlada Download PDF

Info

Publication number
ES2904787T3
ES2904787T3 ES18768795T ES18768795T ES2904787T3 ES 2904787 T3 ES2904787 T3 ES 2904787T3 ES 18768795 T ES18768795 T ES 18768795T ES 18768795 T ES18768795 T ES 18768795T ES 2904787 T3 ES2904787 T3 ES 2904787T3
Authority
ES
Spain
Prior art keywords
ham
pmol
dose
fsh
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES18768795T
Other languages
English (en)
Spanish (es)
Inventor
Saez Joan-Carles Arce
Lisbeth Helmgaard
Bjarke Mirner Klein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ferring BV
Original Assignee
Ferring BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferring BV filed Critical Ferring BV
Application granted granted Critical
Publication of ES2904787T3 publication Critical patent/ES2904787T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES18768795T 2017-09-01 2018-08-31 Composición para la estimulación ovárica controlada Active ES2904787T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17189119 2017-09-01
PCT/EP2018/073442 WO2019043143A1 (en) 2017-09-01 2018-08-31 COMPOSITION FOR CONTROLLED OVARIAN STIMULATION

Publications (1)

Publication Number Publication Date
ES2904787T3 true ES2904787T3 (es) 2022-04-06

Family

ID=59772482

Family Applications (2)

Application Number Title Priority Date Filing Date
ES18768795T Active ES2904787T3 (es) 2017-09-01 2018-08-31 Composición para la estimulación ovárica controlada
ES21196378T Active ES2989511T3 (es) 2017-09-01 2018-08-31 Composición para la estimulación ovárica controlada

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES21196378T Active ES2989511T3 (es) 2017-09-01 2018-08-31 Composición para la estimulación ovárica controlada

Country Status (32)

Country Link
US (2) US11744879B2 (cg-RX-API-DMAC7.html)
EP (3) EP3973982B1 (cg-RX-API-DMAC7.html)
JP (2) JP6856819B2 (cg-RX-API-DMAC7.html)
KR (2) KR20200045543A (cg-RX-API-DMAC7.html)
CN (2) CN111050787A (cg-RX-API-DMAC7.html)
AR (1) AR112541A1 (cg-RX-API-DMAC7.html)
AU (1) AU2018326556B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020003379A2 (cg-RX-API-DMAC7.html)
CA (1) CA3073624A1 (cg-RX-API-DMAC7.html)
CL (1) CL2020000482A1 (cg-RX-API-DMAC7.html)
DK (2) DK3973982T3 (cg-RX-API-DMAC7.html)
EA (1) EA202090480A1 (cg-RX-API-DMAC7.html)
ES (2) ES2904787T3 (cg-RX-API-DMAC7.html)
FI (1) FI3973982T3 (cg-RX-API-DMAC7.html)
HR (2) HRP20241171T1 (cg-RX-API-DMAC7.html)
HU (2) HUE056726T2 (cg-RX-API-DMAC7.html)
IL (1) IL272763B2 (cg-RX-API-DMAC7.html)
JO (1) JOP20200034B1 (cg-RX-API-DMAC7.html)
LT (2) LT3973982T (cg-RX-API-DMAC7.html)
MA (2) MA50034B1 (cg-RX-API-DMAC7.html)
MD (2) MD3675894T2 (cg-RX-API-DMAC7.html)
MX (2) MX2020002235A (cg-RX-API-DMAC7.html)
MY (1) MY200791A (cg-RX-API-DMAC7.html)
PH (1) PH12020500404A1 (cg-RX-API-DMAC7.html)
PL (2) PL3973982T3 (cg-RX-API-DMAC7.html)
PT (2) PT3973982T (cg-RX-API-DMAC7.html)
RS (2) RS65945B1 (cg-RX-API-DMAC7.html)
SG (1) SG11202003840QA (cg-RX-API-DMAC7.html)
SI (2) SI3973982T1 (cg-RX-API-DMAC7.html)
TW (1) TWI749255B (cg-RX-API-DMAC7.html)
UA (1) UA126869C2 (cg-RX-API-DMAC7.html)
WO (1) WO2019043143A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3973982T1 (sl) 2017-09-01 2024-10-30 Ferring B. V. Sestavek za nadzorovano stimulacijo jajčnikov
TWI846743B (zh) 2018-10-17 2024-07-01 荷蘭商菲林公司 用於控制性卵巢刺激之組成物及方法
TW202237173A (zh) * 2020-12-09 2022-10-01 荷蘭商菲林公司 用於受控的卵巢刺激之組成物及方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1250148B2 (en) * 2000-01-27 2008-07-02 Laboratoires Serono SA Use of fsh for treating infertility
US20040248784A1 (en) 2003-06-03 2004-12-09 Marco Filicori Unitary combinations of FSH and hCG
ES2494928T3 (es) * 2007-09-21 2014-09-16 Pharmabrand S.A. Composición que comprende polisacáridos mucilaginosos derivados de Aloe barbadensis combinados con liposomas, procedimiento para la obtención de los mismos y su uso como protector solar, un agente antiacné, un regenerador epidérmico y un hidratante
TWI488640B (zh) 2008-04-16 2015-06-21 菲瑞茵國際中心股份有限公司 藥學製劑
WO2011089602A2 (en) * 2010-01-21 2011-07-28 Ramot At Tel-Aviv University Ltd. Aloe-emodin derivatives and use thereof for the treatment of cancer
US9320778B2 (en) 2010-09-29 2016-04-26 Ferring B.V. Method for controlled ovarian stimulation with combined FSH and hCG
WO2012168680A1 (en) 2011-06-06 2012-12-13 Ferring B.V. Pharmaceutical preparation comprising recombinant fsh
JO3092B1 (ar) 2011-08-08 2017-03-15 Ferring Bv مركب لتحفيز مسيطر عليه للمبيض
AR100132A1 (es) 2014-04-18 2016-09-14 Glycotope Gmbh Un método para hiperestimulación ovárica controlada para estimular el desarrollo de múltiples folículos ováricos en un sujeto femenino
EP3261661B1 (en) 2015-02-26 2023-10-18 Ferring B.V. Menotropin for treating infertility
HUE054300T2 (hu) 2015-04-17 2021-08-30 Ferring Bv FSH-t tartalmazó, meddõség kezelésére szolgáló készítmény
RS61163B1 (sr) 2015-04-24 2021-01-29 Ferring Bv Postupak proizvodnje gonadotrofina
US10906953B2 (en) 2015-06-26 2021-02-02 Ferring B.V. Methods of purification and/or viral inactivation
SI3973982T1 (sl) 2017-09-01 2024-10-30 Ferring B. V. Sestavek za nadzorovano stimulacijo jajčnikov
WO2019211153A1 (en) 2018-04-30 2019-11-07 Ferring B.V. Composition for controlled ovarian stimulation
TWI846743B (zh) 2018-10-17 2024-07-01 荷蘭商菲林公司 用於控制性卵巢刺激之組成物及方法
TW202237173A (zh) 2020-12-09 2022-10-01 荷蘭商菲林公司 用於受控的卵巢刺激之組成物及方法

Also Published As

Publication number Publication date
AR112541A1 (es) 2019-11-06
EP3973982A1 (en) 2022-03-30
PT3675894T (pt) 2022-01-25
US20240024424A1 (en) 2024-01-25
BR112020003379A2 (pt) 2020-08-25
JP7373479B2 (ja) 2023-11-02
DK3675894T3 (da) 2022-01-24
US20200197493A1 (en) 2020-06-25
AU2018326556B2 (en) 2024-09-26
HUE056726T2 (hu) 2022-03-28
PT3973982T (pt) 2024-09-16
JOP20200034A1 (ar) 2020-02-13
US12653864B2 (en) 2026-06-16
HUE068024T2 (hu) 2024-12-28
UA126869C2 (uk) 2023-02-15
JOP20200034B1 (ar) 2024-04-18
EP3973982B1 (en) 2024-07-31
SG11202003840QA (en) 2020-05-28
HRP20211802T1 (hr) 2022-03-04
IL272763B1 (en) 2023-10-01
IL272763B2 (en) 2024-02-01
EP3675894A1 (en) 2020-07-08
MD3675894T2 (ro) 2022-03-31
MA56224B1 (fr) 2024-09-30
FI3973982T3 (fi) 2024-09-23
JP2021046398A (ja) 2021-03-25
LT3973982T (lt) 2024-09-10
CL2020000482A1 (es) 2020-06-26
MA50034A (fr) 2021-05-12
CN111050787A (zh) 2020-04-21
ES2989511T3 (es) 2024-11-26
RS62810B1 (sr) 2022-02-28
WO2019043143A1 (en) 2019-03-07
KR20250078595A (ko) 2025-06-02
EP4427806A2 (en) 2024-09-11
LT3675894T (lt) 2021-12-10
PL3675894T3 (pl) 2022-02-21
PL3973982T3 (pl) 2024-11-04
MA56224A (fr) 2022-04-20
SI3675894T1 (sl) 2022-01-31
CN120617484A (zh) 2025-09-12
SI3973982T1 (sl) 2024-10-30
EP4427806A3 (en) 2024-10-09
IL272763A (en) 2020-04-30
MA50034B1 (fr) 2022-02-28
RS65945B1 (sr) 2024-10-31
JP6856819B2 (ja) 2021-04-14
EA202090480A1 (ru) 2020-07-20
MX2024009224A (es) 2024-08-06
TW201919687A (zh) 2019-06-01
HRP20241171T1 (hr) 2024-11-22
TWI749255B (zh) 2021-12-11
MD3973982T2 (ro) 2024-11-30
US11744879B2 (en) 2023-09-05
MX2020002235A (es) 2020-07-20
AU2018326556A1 (en) 2020-03-05
JP2020528071A (ja) 2020-09-17
CA3073624A1 (en) 2019-03-07
EP3675894B1 (en) 2021-11-03
PH12020500404A1 (en) 2021-03-01
KR20200045543A (ko) 2020-05-04
DK3973982T3 (da) 2024-09-23
MY200791A (en) 2024-01-16

Similar Documents

Publication Publication Date Title
ES3029733T3 (en) Composition for controlled ovarian stimulation
US20240024424A1 (en) Composition for controlled ovarian stimulation
ES2879838T3 (es) Composición que comprende FSH para el tratamiento de la esterilidad
EP3866833B1 (en) Compositions comprising a recombinant fsh for the treatment of infertility
HK40115814A (en) Composition for controlled ovarian stimulation
HK40066975B (en) Composition for controlled ovarian stimulation
HK40066975A (en) Composition for controlled ovarian stimulation
HK40021791B (en) Composition for controlled ovarian stimulation
WO2025149590A1 (en) Compositions and methods for controlled ovarian stimulation
EA046202B1 (ru) Композиция для контролируемой стимуляции яичников
HK40055068A (en) Compositions comprising a recombinant fsh for the treatment of infertility
HK40055068B (en) Compositions comprising a recombinant fsh for the treatment of infertility